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Abstract
The quest for treatment-free remission (TFR) and deep molecular response (DMR) in chronic myeloid leukemia (CML) has
been profoundly impacted by tyrosine kinase inhibitors (TKIs). Immunologic surveillance of residual leukemic cells is
hypothesized to be one of the critical factors in successful TFR, with self-renewing leukemic stem cells implicated in relapse.
Immunological characterization in CML may help to develop novel immunotherapies that specifically target residual
leukemic cells upon TKI discontinuation to improve TFR rates. This review focuses on immune dysfunction in newly
diagnosed CML patients, and the role that TKIs and other therapies have in restoring immune surveillance. Immune
dysfunction and immunosurveillance in CML points towards several emerging areas in the key goals of DMR and TFR,
including: (1) Aspects of innate immune system, in particular natural killer cells and the newly emerging target plasmacytoid
dendritic cells. (2) The adaptive immune system, with promise shown in regard to leukemia-associated antigen vaccine-
induced CD8 cytotoxic T-cells (CTL) responses, increased CTL expansion, and immune checkpoint inhibitors. (3) Immune
suppressive myeloid-derived suppressor cells and T regulatory cells that are reduced in DMR and TFR. (4)
Immunomodulator mesenchymal stromal cells that critically contribute to leukomogenesis through immunosuppressive
properties and TKI- resistance. Therapeutic strategies that leverage existing immunological approaches include donor
lymphocyte infusions, that continue to be used, often in combination with TKIs, in patients relapsing following allogeneic
stem cell transplant. Furthermore, previous standards-of-care, including interferon-α, hold promise in attaining TFR in the
post-TKI era. A deeper understanding of the immunological landscape in CML is therefore vital for both the development of
novel and the repurposing of older therapies to improve TFR outcomes.
Introduction
Chronic myeloid leukemia (CML) is a hematological cancer
characterized by the presence of the BCR-ABL1 oncoki-
nase resulting from the reciprocal translocation t(9;22) in
myeloid stem cells of the bone marrow (BM). The current
mainstays of treatment in CML are tyrosine kinase
inhibitors (TKIs) of which imatinib, nilotinib, dasatinib, and
bosutinib can be used as first-line treatments [1]. The
development of TKIs has profoundly improved prognosis of
chronic-phase CML patients, with treatment aiming to
achieve a deep molecular response (DMR; MR4; BCR-
ABL1mRNA ≤0.01%) to prevent disease progression. This
enables TKI discontinuation in approximately half of
patients who achieve DMR [2]. Quiescent and self-
renewing leukemic stem cells (LSCs) have been impli-
cated in refractoriness and disease progression. These LSCs
can remain, even when there is no measurable residual
disease, and upon changes in the BM microenvironment,
can exit quiescence and drive relapse, representing a bot-
tleneck to cure. Recently, it has also been suggested that
immunologic surveillance of residual leukemic cells is a
critical factor in maintaining treatment-free remission (TFR)
[3–6]. It is thought that when treatment has removed the
majority of CML cells below a certain threshold, the
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leading to sustainable TFR. Therefore, immunological
characterization and understanding of the mechanisms of
immune cell interaction with CML cells in the BM may
help to develop novel immunotherapies that specifically
target residual leukemic cells upon TKI discontinuation to
improve TFR rates. This review focuses on the immune
dysfunction in newly diagnosed CML patients, the role of
TKIs and other therapies in restoring immune surveillance,
and the role of the immune system in maintaining TFR.
Relevant terms used in this review are described in the
Glossary (Table 1).
An overview of immunological profile in
CML and effects of TKI treatment
Immune response to CML
CML is characterized by a period of immune dysfunction
present in patients at diagnosis, prior to the commencement
of TKI therapy. This facilitates tumor progression and self-
preservation, by preventing host development of antileu-
kemia immune responses. Innate immune responses
including dendritic cells (DCs) [7], plasmacytoid dendritic
cells (pDCs) [4], and natural killer (NK) cells [8], have been
noted to be dysfunctional in CML patients, with reductions
in cell count, cytotoxicity, and antigen-presenting function
noted. Adaptive immune responses are dysfunctional in
CML patients at diagnosis, including dysfunctional CD8+
cytotoxic T-cells (CTLs), and expressed/over-expressed
leukemia-associated antigens (LAAs) such as proteinase-1
(PR1) and Wilm’s tumor-1 (WT1) [9–11]. In CML-bearing
mice, CD8+ CTLs also displayed limited cytotoxic activity,
and absence of interferon (IFN)-γ and tumor necrosis factor
(TNF)-α production [12]. Additionally, CML CTLs had
high expression of programmed death 1 (PD1), which
interacts with PD1 ligand (PDL1) expressed on CML cells,
leading to suppression of cell killing ability and subsequent
disease progression [12]. Immune suppressor cells includ-
ing myeloid-derived suppressor cells (MDSCs) and
Table 1 Glossary of terms.
Term Definition/Function
B-cells Upon primary infection or immunization, a small population of antigen-specific B-cells becomes
activated and expands after acquiring T-cell help. Some of these expanded clones then
differentiate into memory B-cells.
CD8+ cytotoxic
T-cells (CTLs)
T-cell exposure to antigens expressed on cancer cells and co-stimulatory signals leads to the
development of effector function and T-cell clonal expansion. T-cell receptors on CD8+ T-cells
bind to antigen, which is held in the major histocompatibility complex (MHC) complex on the
surface of antigen-presenting cells, such as DCs. This then triggers initial activation of the T-
cells.
Dendritic cells (DCs) DCs efficiently process and present antigens to T-cells responsible for the initiation of immune
responses.
Immune checkpoint: cytotoxic T lymphocyte
antigen 4
(CTLA-4)
CTLA-4 is a cell-surface receptor, homologous to CD28, binding to ligands CD80/CD86 on
antigen-presenting cells such as DCs. The binding of CTLA-4 to CD80 and CD86 is
considerably stronger than the affinity of CD28, but unlike CD28 which activates T cells,
CTLA4 delivers an inhibitory signal to T-cell activation. Thus, in cancer, CTLA-4 has
undesirable effects that may prevent T cells from mounting a sufficient immune response.
Immune checkpoint: Programmed death
1 (PD1)
PD1 is one of the crucial immune checkpoint signals and is mainly expressed on mature CTLs.
Interactions of PD1 with its ligand–PD ligand 1 (PDL1) reduce antigen-specific T-cell
activation.
Leukemia-associated antigens (LAAs) LAAs are immunogenic antigens which are able to induce specific T-cell responses and are
target structures relevant for immunological targeting of leukemic cells.
Natural killer (NK) cells NK cells lack T-cell markers but express CD56. Unlike T-cells, NK cells are not restricted to
MHC-I/II molecules and can exert natural cytotoxicity against cancer cells based on signals from
activating and inhibitory cell-surface receptors. CD56dim cells are more differentiated and
cytolytic. A subset of NK cells with CD57 expression further differentiates the functionally
diverse CD56dim subset and are considered ‘memory-like’ NK cells with higher cytotoxicity.
Natural killer cell receptors NK cell receptors are classified into two types—‘inhibitory’ and ‘activating’. Major activating
receptors involved in target leukemic cell killing are KIR2DS, natural cytotoxic receptors
(NCRs)—NKp30, NKp46, and NKp80 and NKG2D. Tolerance of NK cells to normal cells is
attained through their expression of MHC-I-binding inhibitory receptors including killer cell
immunoglobulin-like receptor (KIR)2DL and natural killer group 2A (NKG2A).
Plasmacytoid dendritic cells (pDCs) pDCs are a unique DC subset and produce large amounts of interferon (IFN)-α. Activated pDCs
have strong antigen-presenting capacity, which plays an important role in NK cell recruitment
and T-cell activation.
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regulatory T-cells (Tregs) contribute to T-cell dysfunction
and disease progression in CML, expanding at diagnosis,
and reducing following TKI therapy [13–15]. Notably,
MDSCs stemming from BCR-ABL1 clones downregulate
antitumor immune surveillance, by attenuating the action of
NK and T-cells. These mediate their suppressive activity
through increased reactive oxygen and nitrogen species, and
depletion of arginine (through upregulation of arginase 1)
and cysteine. The latter two amino acids being required for
T-cell function and activation (by antigen-presenting cells
such as DCs), respectively [16].
Immune response after TKI treatment
TKIs have a dual mode of action with a direct inhibitory
effect on BCR-ABL1 tyrosine kinase and immune-
modulatory or suppressive effects. Contradictory results
have been observed between in vitro and in vivo studies.
Several in vitro studies have demonstrated inhibitory effects
of imatinib and dasatinib on immune responses. Both
imatinib and dasatinib reversibly inhibit T-cell proliferation
in vitro but the effects of dasatinib are more profound
[17, 18]. Furthermore, imatinib and dasatinib impair CD8+
CTLs specifically directed against LAA function in vitro
[19, 20], and dasatinib also inhibits NK cell function [21].
In contrast to the in vitro results, clinical data showed that
imatinib or dasatinib treated patients exhibit expansion of
CD8+ CTLs or NK cells which are associated with an
improved response to therapy [22–24]. Furthermore, dasa-
tinib may induce a reversible state of aberrant immune
reactivity, leading to large granular lymphocytic lympho-
cytosis, which is associated with a favorable clinical
response [22]. These differences are likely due to the
inability to recapitulate all aspects of the immune system
and microenvironment in vitro.
Role of immune cells in molecular response after
TKIs
Imatinib-treated patients in chronic-phase have ~20%
chance of achieving DMR in the first 2–3 years of therapy,
with the second generation TKIs dasatinib and nilotinib
potentially permitting a more rapid DMR [25, 26]. The
persistence of detectable leukemic cells while either on- or
off-treatment in DMR are likely governed by immune-
mediated control of residual disease. DMR is associated
with increased NK and CD8+ T-cell numbers, and
decreased MDSCs in the peripheral blood of CML patients
[14]. Likewise, successful TFR has been linked to increased
NK/CD8 T-cells, and decreased Tregs/MDSCs
[3, 22, 27, 28], and low mature (CD86+) pDC frequencies
[4]. In addition, the combination of IFN-α with imatinib has
been demonstrated to improve outcomes [29, 30], with
several clinical studies indicating that IFN-α in combination
with TKI elicits a sustained DMR enabling possible TKI
cessation [31–33]. The immunomodulatory effects of TKIs
in CML patients are summarized in Fig. 1.
Leveraging the immune system to enhance
TFR: targeting specific immune functions
Enhancing or restoring immune effector functions may
provide a pathway to maintaining and increasing TFR in
CML. These approaches may be relatively nonspecific, e.g.,
IFN therapy, or may target specific immune functions. Here
we discuss specific immune effectors including the innate
system NKs, DCs, pDCs and their crosstalk, and
the adaptive system such as CD8+ CTLs, LAAs, immune
checkpoints, B-cells and immunosuppressive Tregs
and MDSCs.
Innate immune responses against CML cells
Innate immune cells can sense cancer cells, antigens, or
changes in the microenvironment, leading to direct immune
effector functions. NK cells and pDCs are the major innate
immune cells and are considered crucial effectors of the
antileukemic immune response. They act as the early
warning system and a bridge to T-cell response or adaptive
immunity.
Natural killer cells
A decrease in the clonogenic frequency and function of NK
cells has been demonstrated in chronic-phase CML patients
at the time of diagnosis, worsening with disease progression
to accelerated- and blast-phase CML [8]. Furthermore,
increased proportions of cytotoxic CD56dim and memory-
like CD57 NK cells are associated with successful TFR in
CML patients after imatinib discontinuation [3, 5, 34].
Natural killer cell receptors
The activation of NK cells is determined by the balance of
signals delivered by activating and inhibitory receptors. NK
cells are a heterogeneous population with respect to the
expression of killer cell immunoglobulin-like receptors
(KIRs), natural killer group 2 (NKG2), and natural cyto-
toxic receptors (NCRs) (Fig. 2).
Impact of TKIs on natural killer cell receptors
Treatment of CML patients with different TKIs alters the
expression of various NK receptors. Dasatinib increases
expression of inhibitory KIR2DL1 receptors, whereas
Improving outcomes in chronic myeloid leukemia through harnessing the immunological landscape 1231
imatinib increases expression of activating receptors
including NKp30, NKp46, NKp80, and NKG2D [35].
Downregulation of inhibitory receptor NKG2A by dasatinib
enhances NK cell cytotoxicity and results in more rapid
treatment responses in CML patients [23]. NK receptors
also play an important role in maintaining DMR and TFR,
with expression of activating receptors NKp30, NKp46,
NKG2A, NKG2C, and NKG2D restored to normal levels in
molecular response compared with their downregulation at
diagnosis [14]. KIRs have extensive polymorphisms, and it
has been suggested that KIR genotypes correlate with NK
cell immunity against CML and sustained DMR after dis-
continuing TKI treatment [6, 36]. Although no difference
has been observed in KIR genotypes (such as KIR2DL2,
KIR2DL5, and KIR3DS1) among non-relapsing, early and
late relapsing groups in patients from the TFR clinical trial
EURO-SKI [3], several studies have demonstrated that
patients with genotypes KIR2DL5B and KIR2DL2 achieve
lower rates of cytogenetic and molecular remission in
response to TKIs, implying that specific KIR genotypes or
high numbers of inhibitory KIR genes can suppress NK cell
toxicity against CML cells [37, 38]. Furthermore, expres-
sion of KIR2DL2/DL3/DS2 was restored to normal levels
following achievement of major molecular response (MMR;
BCR-ABL1 ≤ 0.1%) and molecular response4.5 (MR4.5, BCR-
ABL1 ≤ 0.0032%) compared with reduced levels at diag-
nosis [14].
A more recent study shows that acute myeloid leukemia
(AML) LSCs that express stress-induced ligands NKG2DLs
for receptor NKG2D are cleared by NK cells, whereas
NKG2DL-negative LSCs isolated from the same individual
escape cytotoxic NK cells. These NKG2DL-negative LSCs
not only selectively survive chemotherapy but also evade
immune surveillance [39]. Thus, evaluating both inhibitory
and activating receptors to assess NK cell function overall
would give a better indication of immune function in CML.
Enhanced NK cell immunity, including NK cell receptors
engaged with ligands expressed on CML cells, provides a
promising immune therapeutic target to achieve TFR. NK
cell modulating agents, such as lenalidomide, and the
adoptive transfer of NK cells are currently undergoing
clinical trials in other hematological malignancies. Lenali-
domide shows potential in TFR by virtue of T and NK cell
proliferation and activation, and enhanced NK cytotoxicity.
A recent phase I trial showed a sustained BCR‐ABL1 level
≤0.0032%, however, the trial was prematurely stopped due
to concerns about thrombotic risk [40]. Interestingly,
adoptive transfer of CNDO-109-activated allogeneic NK
Fig. 1 Immunomodulatory
effects of tyrosine kinase
inhibitors (TKIs) in chronic
myeloid leukemia (CML)
patients. Upper diagram—CML
effects on untreated immune
cells. Lower diagram—effects
on immune cells after TKI
treatment, including cytotoxic T-
cells (CTLs), natural killer (NK)
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cells resulted in enhanced cytotoxicity and NK cell activa-
tion in high-risk patients with AML in phase I trials [41].
Alternatively, adoptively transferred cytokine-induced
memory-like NK cells improved clinical responses in
AML patients [42].
Dendritic cells
BCR-ABL1-positive DCs can be generated from peripheral
blood mononuclear cells or CD34+ progenitor cells. They
have an impaired capacity to capture and process antigens,
and defective cell migration compared to DCs from healthy
donors [7]. Research has shown that after 3–6 months of
imatinib treatment, DC numbers partially recover but do not
reach levels observed in healthy individuals [43]. However,
there are contradictory findings regarding the capability of
BCR-ABL1-expressing DCs in CML. In one study, DCs
generated from blood progenitors of CML patients induced
a primary CML-directed cytotoxic immune response
in vitro [44]. In contrast, in another study, CML-derived
DCs displayed reduced antigen-presenting function, low
maturation status, and impaired homing to secondary lym-
phoid organs when compared to control DCs in a retroviral-
induced murine CML model [45]. In AML, leukemic DCs
also promoted T-cell anergy and the generation of Treg cells
that are specialized in immune suppression, through upre-
gulation of PDL1 on leukemic DCs [46]. Taken together,
functional deficiencies of BCR-ABL1-expressing DCs may
contribute to the escape from immunosurveillance observed
in CML.
Plasmacytoid dendritic cells
pDCs have emerged as crucial effectors in innate immune
responses in CML. Before treatment, CML patients have
reduced numbers of circulating pDCs. Moreover, patients
who were in complete cytogenetic or molecular response
after imatinib treatment restored their blood pDCs both
quantitatively and functionally and were comparable to
healthy donors [47]. Contrary to previous studies, data from
the EURO-SKI and German CML-V TIGER study recently
showed that high numbers of activated CD86+ pDCs were
observed in CML patients with molecular recurrence after
TKI discontinuation. This was associated with T-cell
exhaustion with increased PD1 expression on CD8+
CTLs and PR1-specific antileukemic CD8+ CTLs. The
authors suggest that T-cell exhaustion with CD86+ pDCs
contributes to recurrence risk and that low CD86+ pDC
might be predictive of TFR [4]. Moreover, a recent concept
was raised by Inselmann et al., based on the German CML-
V study [48], in which low frequencies of BCR-ABL1+
pDCs (transdifferentiated from LSCs) may regulate antil-
eukemic immunity in the early (pre-leukemic) evolution of
CML as well as in DMR. However, high numbers of BCR-
ABL1+ pDCs can also aberrantly express multiple inflam-
matory cytokines/chemokines that drive chronic
Fig. 2 The major natural killer (NK) cell receptors affected in
chronic myeloid leukemia (CML). Progression of NK cells from
quiescence to activation is mediated by activating (in green) and
inhibitory (in red) receptors. The balance between both receptor sub-
types determines if NK cells are cytotoxic. The inhibitory killer cell
immunoglobulin-like rectors (KIRs) and natural killer group 2A
(NKG2A) receptor conduct inhibitory signals to restrain NK cell
function to avoid killing normal cells under physiological conditions.
In contrast, activating receptors such as natural cytotoxic receptors
(NCRs)—NKp30, NKp46 and NKp80, and NKG2D trigger NK cell
activation following binding to ligands upregulated on target cells
undergoing stress and/or infection. PD1: programmed death 1. Illus-
tration was created with BioRender.com.
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inflammation, such as in CML patients with molecular
recurrence, which stimulates CML-LSC persistence and
immunosuppression. Using RNA sequencing, this study
also revealed a strong inflammatory gene expression sig-
nature in CML-pDCs at diagnosis. Patients with high pDC
counts (expanding with BCR-ABL1+ stem cell mass) at
diagnosis achieved inferior rates of DMR under nilotinib,
unless nilotinib therapy was combined with IFN, which
strongly suppressed circulating pDC numbers [48]. The
authors therefore suggest that high numbers of BCR-ABL1+
pDCs may be an early biomarker of failure to achieve DMR
with reduced likelihood of TFR.
Interaction of natural killer and dendritic cells
NK-DC bi-directional crosstalk can lead to activation of
both cell types including NK cell lysis of autologous DCs,
production of proinflammatory cytokines, and stimulation
of T-cell responses. A reciprocal relationship exists, with
NK cells promoting DC maturation and activated NK cells
having the ability to kill DCs that fail to undergo proper
maturation through engagement of the activating receptor
NKp30 [49]. In vitro studies have demonstrated that culture
of activated NK cells with immature DCs at low NK/DC
ratios promotes DC maturation, whereas a higher NK/DC
ratio can result in NK cell-mediated killing of DCs [50].
This may add a new predictive indicator of immune system
configuration for maintaining TFR. Moreover, it has been
suggested that functionally defective pDCs interact with NK
and T-cells leading to immunosuppression in the BM milieu
in patients with multiple myeloma by engaging the
PD1 signaling axis [51]. Future studies are needed to elu-
cidate the interaction between NK cells and pDCs, and
whether NK and T-cell functions are regulated by pDCs in
CML after TKI cessation.
Adaptive immune responses against CML cells
CD8+ cytotoxic T-cells
In CML at diagnosis, CD8+ CTLs are functionally
exhausted with limited cytotoxicity, and impaired ability
to expand and produce proinflammatory cytokines [52].
However, expansion of CD8+ CTLs was seen in CML
patients treated with dasatinib, concomitant with an
improved response to therapy [22, 53]. Furthermore,
patients with DMR exhibited restored CD8+ CTLs with
decreased inhibitory molecule PD1 [9, 14]. Patients who
obtained TFR after IFN-α treatment also showed upre-
gulation of CD8+ CTLs [54]. In addition, T-cell receptor-
Vβ repertoire expression indicated T-cell dysfunction in
CML patients, and an increase in the effector and memory
CD8+ CTL fraction was reported in a CML patient
maintaining DMR for 2.4 years after dasatinib cessation
[55, 56].
CD62L, an effector memory T-cell marker, mediates T-
cell trafficking to secondary lymphoid tissues and is cor-
related with treatment responses in CML. Its down-
regulation may impair effector CTL function in CML and
abrogate antileukemic immune control. CD62L is shed from
T-cells by the matrix metalloproteinase TNF-α-converting
enzyme, and subsequently the soluble form of CD62L
(sCD62L) can be detected in plasma. High CD62L+
expression on T-cells and concomitant reduced sCD62L
levels were linked to superior molecular response to nilo-
tinib therapy in CML. In the same study, TNF-α-converting
enzyme was increased at diagnosis and significantly
decreased during nilotinib treatment [57], therefore high-
lighting CD62L as a predictor of molecular response to
TKI. Similar studies have shown that CD62L expression
was effectively restored to normal levels in CML patients
achieving MMR and MR4.5 on imatinib, nilotinib, and
dasatinib [14]. Active immunotherapy, aiming at expansion
and effector function of CTLs, may represent a powerful
approach to target CML cells.
Leukemia-associated antigens
LAAs are over-expressed or aberrantly expressed in CML.
CTLs target numerous LAAs on leukemic cells, including
BCR-ABL1 fusion peptide, PR1, and WT1, which can lead
to LAA-specific CTL induction, thus enhancing antileu-
kemic immune responses. A blunted antigen-specific CTL
response to LAAs was observed in CML patients at diag-
nosis. These immune effector responses were restored to
normal levels in CML patients who achieved MMR and
MR4.5 on TKIs and were retained in TFR patients who
achieved a durable DMR on imatinib [14]. PR1 is an HLA-
A2-restricted peptide derived from both proteinase 3 and
neutrophil elastase. Induction of PR1-specific CD8 CTLs
may contribute to sustained molecular response in CML
patients on IFN-α maintenance after imatinib/IFN-α com-
bination therapy and cytogenetic remission in CML patients
after allogeneic hematopoietic stem cell transplantation
(HSCT) [10, 31]. Moreover, among these LAA targets,
WT1 is over-expressed in myeloid malignancies. A vaccine
targeting WT1 was reported to be well-tolerated in AML
patients with regression of measurable residual disease [58],
and in an imatinib‐treated CML patient, WT1 vaccination
also induced a reduction in measurable residual disease
[11]. Furthermore, BCR-ABL1 peptide immunization
induced an anti-BCR-ABL1 T-cell response that correlated
with a subsequent decrease of at least 1 log of BCR-ABL1
transcripts in imatinib-treated CML patients [59]. Lastly,
CXorf48-specific CTLs, a novel LAA, were detected in
patients who achieved TFR; in contrast CXorf48-specific
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CTL-negative patients had high molecular recurrence rates
[60]. Vaccination with LAA-peptides may therefore induce
specific expansion of CTLs, and together with safety
demonstrated in clinical trials, in particular for WT1
[58, 61], highlights the importance of LAAs as relevant
clinical immunotherapy targets in CML.
Immune checkpoint: programmed death 1
The three best described checkpoint molecules—PD1, T-
cell immunoglobulin and mucin domain 3 (TIM3), and
cytotoxic T lymphocyte antigen 4 (CTLA-4), act as inhi-
bitory receptors of T-cells and have been associated with
immune evasion in CML. CML-specific CTLs were char-
acterized by the high expression of PD1, whereas their
target leukemic cells expressed higher levels of its ligand,
PDL1, in a CML mouse model and in patients [9, 12, 34].
PD1/PDL1 interactions contribute to functional T-cell
impairment, which fails to eliminate measurable residual
disease and may be related to leukemia relapse. Blocking
this PD1/PDL1 interaction restored CML-specific CD8+
CTL function and prolonged survival of mice with blast-
phase CML, suggesting that CD8 CTLs are crucially
involved in the control of CML progression [12]. Further-
more, BM PD1+ TIM-3-CD8+ T-cells were correlated
positively with failure to reach DMR [9]. Patients in MR4.5
also exhibited reduced PD1 expression on CD4+ and CD8
+ T-cells, concomitant with increased NK and T-cell
immune responses, suggesting that therapeutic methods to
enhance NK cell function and immunogenic CTL responses
or blocking aberrant PD1 signaling may result in greater
success in TKI cessation studies [14]. Clinical trials to
explore this in patients include the PD1 inhibitor nivolumab
in combination with dasatinib (ClinicalTrials.gov Identifier:
NCT02011945), and the PDL1 inhibitor avelumab in
combination with TKIs in the ACTIW trial (ClinicalTrials.
gov Identifier: NCT02767063). Although the mechanism of
action in CML is uncertain, PD1 has recently been found to
be expressed on NK cells. PD1/PDL1 blockade may
therefore mediate some of its therapeutic effects through
eliciting a strong NK response as demonstrated in murine
cancer models [62].
Immune checkpoint: cytotoxic T lymphocyte antigen 4
In CML an increase in CTLA-4 expression on T-cells has
been noted at diagnosis [9]. The EURO-SKI trial also
recently reported that the CD86 receptor, ligand of CTLA-4,
was increased on pDCs, and this was associated with
exhaustion of CD8+ CTLs and higher recurrence risk after
TKI cessation. This study raised the concept that PD1- or
CTLA-4-blocking antibodies given directly prior to and
temporarily after TKI discontinuation may block the
immune inhibitory effects of pDCs on T-cells [4]. It is
therefore plausible that CML cells may escape T-cell killing
by promoting inhibitory feedback of CTLA-4 signaling,
mediated via pDCs. A clinical trial (NCT01822509) is cur-
rently evaluating the efficacy of ipilimumab (anti-CTLA-4)
in combination with nivolumab (anti-PD1) in patients with
hematological malignancies, including CML.
B-cells
In CML, reduced immunoglobulin (Ig) levels and hypo-
gammaglobulinemia were found in patients previously
exposed to IFN-α and then treated with imatinib. The
reduction of Ig levels was greater in patients with cytoge-
netic response, suggesting an effect of imatinib on dysre-
gulation of B-cell function [63]. Moreover, loss of IgM
memory B-cell subsets in CML patients at diagnosis and
following complete cytogenetic remission on imatinib has
been observed, suggesting that TKIs might interfere with
the production and maintenance of B-cell memory [64].
Memory B-cell expression also failed to normalize despite
achievement of DMR on TKIs [14]. Variable effects on Ig
levels with TKIs include reduction in plasma IgA and IgG
with imatinib, whilst IgM is reduced with dasatinib
12 months after treatment [65]. The impact of TKIs on B-
cell response to influenza and pneumococcal vaccination in
CML patients has found dose-dependent suppression of B-
cell receptor signaling tyrosine kinases, such as Bruton’s
tyrosine kinase, and downstream phospholipase C-γ-2.
These kinases are essential in B-cell signaling and survival,
resulting in a TKI-induced, off-target kinase impairment of
B-cell responses in CML patients [64].
Immunosuppressive cells—T regulatory and
myeloid-derived suppressor cells
Tregs and MDSCs represent two immunosuppressive cell
populations increased in CML patients at diagnosis; they
elicit T and NK cell anergy, inhibiting immune-mediated
attack against leukemic cells. Imatinib, dasatinib, and
nilotinib attenuated the number of Tregs and MDSCs in
patients with CML. Moreover, low numbers of Tregs were
observed in patients achieving DMR following dasatinib
treatment, with Tregs showing a strong inverse correlation
with NK cell differentiation, indicating that inhibition by
dasatinib enhances NK cell-mediated killing of leukemic
cells [15]. Reduced Tregs were also associated with suc-
cessful maintenance of TFR in CML [66]. Furthermore,
reduced numbers of monocytic MDSCs were associated
with increased NK and effector T-cell cytolytic function,
and decreased T-cell PD-1 expression in CML patients with
MR4.5 following TKI treatment [14]. It is known that
MDSCs can suppress effector T-cells as well as induce
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Tregs via the aberrantly expressed PD1/PDL1 pathway,
thus promoting tumor development. MDSCs were found to
be part of the tumor clone displaying BCR-ABL1 expression
[67]. It is likely that TKIs target MDSCs that are part of the
BCR-ABL1-positive leukemic clone and inhibit Treg acti-
vation, thus restoring NK cell killing and effector T-cell
function via PD1 signaling [14]. Beyond the direct sup-
pressive effects of MDSCs on NK and T-cells, other
indirect mechanisms have been identified, including accu-
mulation of reactive oxygen species and nitric oxide, and
depletion of L-arginine and cysteine [67].
Leveraging the immune system to enhance
TFR in CML: nonspecific immune approaches
Targeting of specific immune effectors to enhance or sustain
TFR in CML is one of the goals of precision oncology.
However, the repurposing of traditional, nonspecific mod-
ulators of the immune system such as IFN-α, donor lym-
phocyte infusion (DLI), and mesenchymal stromal cells
(MSCs) in the BM microenvironment, are emerging as
therapeutic targets in the context of TFR in CML.
Activating effector immune cells by IFN-α therapy
Prior to imatinib, IFN-α was the gold standard therapy for
CML patients, with a small proportion of patients under-
going treatment with IFN-α alone maintaining durable
remission. Of note, a percentage of these patients may
sustain long-term durable remissions after discontinuation
of treatment [68]. In contrast to imatinib, evidence suggests
that IFN-α preferentially targets LSCs responsible for CML
recurrence. Angstreich et al. showed that IFN-α was toxic to
the primitive progenitors from CML patients responsible for
the maintenance of long-term cultures, whereas imatinib
preferentially targeted more mature and differentiated CML
progenitors that constitute the bulk of leukemia [69]. These
findings may underlie the slower but more persistent clinical
effects of IFN-α in comparison to imatinib. Data from a
mouse model also showed that IFN-α activates dormant
hematopoietic stem cells (HSC)—exiting G0 phase and
entering an active cell cycle, and thus sensitizing them to
subsequent killing by 5-fluoro-uracil [70]. In addition, IFN-
α may attenuate CML by activating PR1-specific CD8+
CTLs and NK cells, and inducing DC differentiation with
specific antileukemic function [10, 31, 71]. Therefore, IFN-
α has made a comeback as a viable therapeutic option in
CML for its unique activity against dormant CML stem
cells and activating the specific immunity that is essential
for maintaining DMR and possible TKI cessation. Recently,
several clinical trials have found that the use of IFN-α in
combination with TKIs elicits a sustained DMR and
potential for TKI discontinuation [31–33]. Interestingly,
CML patients receiving upfront IFN-α plus imatinib ther-
apy, followed by low-dose IFN-α maintenance, showed low
rates of early progression and a trend towards deepening of
their molecular response [31]. A median 8-year follow-up
of the same patient cohort reported that IFN-α enabled
therapy discontinuation in most patients provided they had
been in MMR at the time of imatinib discontinuation [33].
However, more recently a study reported that CML patients
with long-term combination treatment of IFN-α and TKI
(median 3.4 years) exhibited an enhanced immunosup-
pressive state which was associated with upregulation of
immunosuppressive cells including Tregs, MDSCs and
CD4+ PD1+ cells, and expansion of immature NK cells
[72]. Co-administration of IFN-α may therefore offer a
strategy to support long-term TKI discontinuation, but must
be counterbalanced by close monitoring of immunosup-
pressive cell subsets.
Leverage existing immunological approaches—
donor lymphocyte infusion
DLI is the treatment of choice for CML patients in relapse
after allogeneic HSCT, with the seminal work of Kolb
et al. demonstrating the profound efficacy in inducing
remission and cure in chronic-phase CML [73]. Allo-
geneic HSCT remains an important rescue strategy for
CML patients who do not respond adequately to TKI
therapy or patients with advanced phase disease. DLI has
strong antileukemic effects, and can induce a direct graft-
versus-leukemia (GVL) reaction and restore complete
remission for CML patients who relapse after allogeneic
HSCT [74]. Graft-versus-host disease (GVHD) and mar-
row aplasia are the two major complications of DLI,
which are greatly reduced with escalating dose regimens,
while preserving the GVL effect. Responses to DLI,
including the incidence of GVL and GVHD in CML, have
been discussed elsewhere [75].
In recent years, TKIs have been used as pretransplant and
maintenance therapy following allogeneic HSCT in CML,
especially in advanced phase disease. Historically, in TKI
naïve patients, imatinib resulted in higher rates of overall
and disease-free survival than DLI in CML relapse after
HSCT [76]. TKIs were also found to be better tolerated than
DLI and produced durable remission in most patients with
CML who have relapsed disease, especially chronic-phase
relapses, after HSCT [77]. However, the ability to prescribe
a TKI post-HSCT is dependent on whether or not a patient
has demonstrated resistance/intolerance to all available
TKIs pre-transplant, and this may limit therapeutic options,
likely making DLI preferable. In terms of synergistic
effects, contradictory results have been published. More
than a decade ago, several small studies demonstrated
1236 Y.-C. Hsieh et al.
benefit in combining DLI with TKI in CML relapse after
HSCT such that rapid and durable remissions were
observed [78]. However, more recent studies have demon-
strated that TKI-only had the highest cumulative incidence
of complete molecular remission and lowest cumulative
incidence of death when compared to DLI alone or TKI+
DLI, although these results failed to reach statistical sig-
nificance, suggesting that TKI salvage continues to provide
significant survival in CML relapse following HSCT
[79, 80]. Taken together, the data on the comparison
between TKI and DLI are still limited and the exact role of
TKI in CML relapse post-HSCT needs to be further defined.
Immunomodulator mesenchymal stromal cells
MSCs, mainly from BM, have immunoregulatory and
immunosuppressive roles in promotion of tumor growth
and drug-resistance in CML. They are considered critical
contributors to leukemogenesis and the protection of
CML-LSCs from TKI therapy. Although MSCs from
CML patients do not express BCR-ABL1, they may play
an essential role in the activation of alternative survival
signaling pathways, such as the Wnt pathway, indirectly
protecting leukemic cells from therapy [81]. MSCs from
untreated CML patients, or from patients on long-term
treatment with imatinib, had a lower frequency but
otherwise normal functional integrity. In vitro studies
indicate that these suppressive effects of imatinib on
MSCs are reversible, with MSC proliferation recovering
on drug discontinuation [82]. This has implications for
both the bone remodeling side effects and duration of
treatment with imatinib. Gene expression profiling of
MSCs from CML patients at both diagnosis and
achievement of DMR after imatinib or dasatinib treat-
ment, found similar gene expression aberrations at both
stages. This study suggested that MSCs exhibited an
abnormal gene expression pattern which might have been
established during leukemogenesis within the BM niche
and persisted in patients with DMR [83]. Recently an
in vitro study reported that MSCs promoted TKI-
resistance through a BCR-ABL1-independent mechan-
ism via upregulation of the IL-7/JAK1/STAT5 pathway,
with IL-7 or JAK1 inhibition sensitizing CML cells to
TKI therapy and reducing resistance [84].
MSCs also play a pivotal role in maintaining normal
HSCs and LSCs within the BM niche. CXCL12 is the major
chemoattractant for maintenance of HSCs and development
of B-cells, pDCs, and NK cells, and plays a major role in
their localization to regulatory niches. In CML patients,
CXCL12 levels are reduced in the BM niche and only
partially restored after imatinib treatment. Furthermore,
targeted deletion of CXCL12 from MSCs reduced normal
HSC numbers but promoted LSC expansion by increasing
LSC self-renewing cell divisions, possibly through
enhanced EZH2 epigenetic activity. The authors concluded
that in CML, the CXCL12-expressing MSC niche maintains
LSCs in a quiescent, TKI-resistant state [85]. Furthermore,
MSCs from CML patients induced immunosuppression by
reducing T-cell proliferation via granulocyte-like-MDSCs.
It was suggested that MSCs over-expressing immunomo-
dulatory factors—TGFβ, IL-6, and IL-10, could be involved
in MDSC activation [86]. This supports the concept that
MSCs contribute to CML disease development and pro-
gression through immunosuppressive properties. Addition-
ally, MSCs in AML have been observed to deliver
functional mitochondria to leukemic cells, in particular
during chemotherapy, thus enhancing leukemic cell survival
rate. Cytochalasin blocks this transfer, supporting the
potential involvement of nanotubes in this process [87].
These findings are further supported by evidence that LSCs
from TKI-resistant CML patients also rely on mitochondrial
transfer. Together these data have led to the clinical use of
tigecycline in combination with imatinib for TKI-resistant
CML [88].
Immunotherapy in TKI-resistant mutations
and blast-phase patients
IFN-α
As monotherapy or combination with TKIs may provide
scope to mitigate TKI-resistant mutations and maintain
response in CML. A TKI-resistant patient treated initially
with IFN-α monotherapy for 8 months lost the T315I
mutation but acquired a new F359V mutation. Further
combination treatment with dasatinib resulted in complete
hematologic response [89]. Another patient with hemato-
logical relapse due to T315I mutation after prolonged
(35 months) imatinib treatment, underwent subsequent IFN-
α monotherapy for 10 weeks, resulting in sustained DMR
[90]. IFN-α individualized therapy in four patients with
dasatinib-resistant T315I or M351T/F317L mutations, led
to MMR or DMR whilst reducing mutations to undetectable
levels. The authors suggested that the principal mechanism
underlying this success was biphasic—with immune acti-
vation induced by dasatinib pre-treatment followed by
restoration of immunological surveillance after application
of IFN-α therapy [91]. In vitro, IFN-α combined with
arsenic trioxide, synergized to inhibit proliferation and
induce apoptosis of imatinib-resistant CML cell lines, whilst
in vivo murine models showed significantly prolonged
survival of primary T315I-CML mice whilst dramatically
impairing disease engraftment in secondary mice [92]. IFN-
α may thus provide an alternative therapeutic approach in
selected TKI-resistant mutation positive CML patients,
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particularly those ineligible for alternative options such as
BM transplantation.
Chimeric antigen receptor T-cells
Chimeric antigen receptor (CAR)-T-cells are one of the
emerging clinical success stories in B-cell malignancies,
and translating this success to the field of myeloid malig-
nancies holds promise. IL1 receptor accessory protein
(IL1RAP), a co‐receptor for the IL1 and IL33 receptors, is
an intriguing rare cell-surface marker that is expressed on
CML cells but not normal HSCs [93]. Both in vitro and
in vivo studies suggest that CAR-T-cells targeting IL1RAP
specifically kill quiescent CML stem cells [94]. Addition-
ally, anti-IL1RAP-CAR-T therapy has a favorable side
effect profile, with no major deleterious effects on healthy
hematopoietic cells both in vitro and in vivo, and without
some of the adverse events more commonly associated with
CAR-T therapy such as off-target toxicity or tumor lysis
syndrome. A combined CAR-T and TKI approach has also
been used in limited clinical cases to eliminate CML stem
cells. A lymphoid blast-phase CML patient harboring T315I
mutation achieved complete molecular remission and
returned to chronic-phase with combination anti-CD19
CAR-T therapy and dasatinib treatment. The authors
hypothesize that anti-CD19 CAR-T cleared the T315I
mutation through elimination of all CD19+ cell clones,
which resulted in clinical re-sensitization to dasatinib [95].
Anti-CD19-CAR-T-cells may also exhibit potent cytotoxic
activity against RUNX1 mutations in blast-phase CML
patient cells, with an additive effect to imatinib. This has
been observed ex vivo in both a RUNX1pR204Q mutated
patient who carried T315I resistance mutation, and in a
RUNX1pR162K mutation with no TKI-resistance mutation
[96]. In the quest to eradicate CML LSC, CAR-T-cell
therapy represents a paradigm shift in conventional anti-
cancer chemotherapy. CAR-T-cells may confer particular
therapeutic benefit to TKI-resistant/intolerant, young or
advanced phase CML patients.
Other targeted therapies
Other targeted immunotherapy approaches are currently in
development, including the anti-CD33 antibody gemtuzu-
mab ozogamicin in myeloid blast-phase, and blinatumo-
mab, a bispecific anti-CD3/CD19 T-cell engager (BiTE),
consisting of bivalent bispecific antibody variable fragments
linked together [97]. This creates a molecule with distinct
binding properties at each end, with one binding CD3 on
the surface of T-cells, and the other CD19 on B-cells. Bli-
natumomab is approved for use in relapsed B-cell acute
lymphoblastic leukemia (B-ALL) and may also have a role
in treatment of lymphoid blast-phase CML.
Differences and similarities of immune
profiles in CML versus other leukemias
Comparing immune profiles in CML and other leukemias
may provide insight into future shared treatment strate-
gies. Furthermore, the majority of studies on CML
immunology have been conducted with peripheral blood
samples, with BM proposed as the standard tissue for
immuno-oncological studies as it represents a particularly
immunosuppressive microenvironment in CML [9]. One
such area investigated recently is the BM immunological
landscape of CML, AML and B-ALL patients at diagnosis
compared to heathy donors. Using multiplex immuno-
histochemistry and computerized image analysis [98],
Bruck et al., found that immune checkpoint lymphocyte-
activation gene 3+ T-cells were depleted in CML, AML
and B-ALL. However, in CML the expression pattern of
immune checkpoint TIM3 differed from other immune
checkpoints by being notably enriched compared with
other leukemias (AML, B-ALL) or healthy donors. The
reason for this contrast remains unknown but might pro-
vide the basis for novel immunomodulatory approaches or
immune checkpoint inhibitors. Additionally, this study
also observed a higher macrophage polarization toward
M1 and M2 phenotypes and an abundance of MDSC-like
cells in CML BM, compared with AML or healthy BM,
although the authors recognized that the MDSC-like cells
may partly represent expanded malignant CML cells.
Previous studies by Bruck et al., demonstrated that TKI
treatment responses are more potent in patients with less
exhausted T-cells. Although this may simply reflect dis-
ease aggressiveness, the authors’ note that this may also
be due to off-target immunomodulatory effects of TKIs
enhancing pre-existing antileukemic immune responses or
dampening immunosuppressive cells such as Tregs. Per-
haps more importantly, BM T-cells may provide a means
of predictive modeling in CML, with regression modeling
indicating that low CD4+ T-cell proportion, high PD1+
TIM3-CD8+ T-cell proportion, and high neutrophil count
in peripheral blood are predictors of poorer TKI response
[9]. Furthermore, comparative immune profiling in leu-
kemias points towards the development of immunohisto-
chemical scoring tools for predicting TKI response
in CML.
Nonimmune mechanisms of TFR loss in CML
Although this review focuses on immune mechanisms of
TFR failure, nonimmune mechanisms of TFR escape
including residual LSCs, quiescent LSCs insensitive to TKI,
and senescence/clonogenic exhaustion of BCR-ABL1 cells,
are nonetheless closely intertwined with immune function.
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LSC persistence, both on-therapy and off-therapy during
TFR, have been noted in the majority of CML patients [99].
In TFR specifically, the majority of failures occur within the
first 6–12 months, implicating residual LSC populations in
these early recurrences, suggesting control but not elim-
ination by TKI therapy. Recently, results of long-term fol-
low-up of patients from the Imatinib Suspension and
Validation study, a multi-center trial of imatinib dis-
continuation in CML patients with undetectable DMR,
found an inverse relationship between patient age and risk
of relapse, with the suggestion of age-related exhaustion of
clonogenic capacity of BCR-ABL1 quiescent CML cells.
Additionally, the majority of non-relapsed cases had at least
1 positive BCR-ABL1 transcript, indicating an unknown
mechanism for self-limiting growth of leukemic cells
despite treatment absence [99]. TFR loss may also be
viewed as a stochastic event, with processes underlying
HSC division unknown. Therefore, the quiescent BCR-
ABL-positive LSC only becomes of clinical significance
when the cell divides, with resulting loss of TFR. Some data
suggests that this occurs by chance, and the loss of TFR
after TKI discontinuation has been likened to the concept of
cancer latency, although the two processes are biologically
distinct [100].
Conclusions
The emerging landscape of immune dysfunction and
immunosurveillance in CML highlights the critical impor-
tance of the immune system in optimizing treatment
responses in CML. Newer precision oncology approaches
targeting specific immune functions, such as LAA vaccines,
immune checkpoint PD1 inhibitors, and CAR-T-cell ther-
apy hold great promise. Intriguingly, previous standard-of-
care therapy, IFN-α, exhibits nonspecific, untargeted effects
on the immune system, has been repurposed to enhance
TFR in the TKI era. Together, specific and nonspecific
immune effectors may make the concept of “operational
cure” a reality for the vast majority of patients in the coming
decade.
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